MedPath

The Impact of Body Mass Index on the Endometrial Microbiome in IVF Treatments. Tampere Infertility Microbiome Project (TIMP).

Not Applicable
Completed
Conditions
Infertility, Female
Registration Number
NCT04168567
Lead Sponsor
Tampere University Hospital
Brief Summary

This study project is an observational trial involving 90 patients suffering from male type infertility. The patients are divided in two groups (45 patients per group) based on their body mass index (BMI).

Detailed Description

This study (Tampere Infertility Microbiome Project, TIMP) aims to clarify the differences in the microbiome variety between obese and normal-weight patients. The first group will consist of patients with the body mass index (BMI) over 30 kg/m², while the second group will include patients with a healthy weight BMI under 25. The samples will be collected at the time of embryo transfer and analyzed in a laboratory specialing in next-generation sequencing (NGS) techniques.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
91
Inclusion Criteria
  • Patients with male infertility scheduled for IVF treatment and fresh embryo transfer
  • Primary or secondary male-type infertility
  • BMI over 30 kg/m² or under 25 kg/m²
  • Patient's willingness to participate
Exclusion Criteria
  • Patients with endometriosis or adenomyosis
  • Use of antibiotics during IVF treatment or oocyte retrieval
  • Technical diffuculties in embryo transfer or no embryos available for transfer

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Microbiome variety between groupsthrough study completion, 1-2 years from the starting date

This study aims to investigate differences of endometrium microbiome and continuum of microbiota from anal to reproductive tract site between obese and normal-weight patients. Samples will be collected at the time of embryo transfer using embryo transfer catheter. The study will also examine pregnancy outcomes and microbiome differences in pregnant patients.

Secondary Outcome Measures
NameTimeMethod
Ongoing pregnancy rateup to 2-3 months

Ongoing pregnancy rate

Trial Locations

Locations (1)

Tampere University Hospital

🇫🇮

Tampere, Finland

Tampere University Hospital
🇫🇮Tampere, Finland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.